Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

D Meulendijks; W Jacob; EE Voest; M Mau-Sorensen; M Martinez-Garcia; A Taus; T Fleitas; A Cervantes; Martijn Lolkema; M H G Langenberg; Maja de Jonge; Stefan Sleijfer; JY Han; A Calles; E Felip; SW Kim; JHM Schellens; S Wilson; M Thomas; M Ceppi; G Meneses-Lorente; I James; S Vega-Harring; R Dua; M Nguyen; L Steiner; C Adessi; F Michielin; B Bossenmaier; M Weisser; U N Lassen

doi:10.1158/1078-0432.ccr-17-0812

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

D Meulendijks, W Jacob, EE Voest, M Mau-Sorensen, M Martinez-Garcia, A Taus, T Fleitas, A Cervantes, Martijn Lolkema, M H G Langenberg, Maja de Jonge, Stefan Sleijfer, JY Han, A Calles, E Felip, SW Kim, JHM Schellens, S Wilson, M Thomas, M CeppiG Meneses-Lorente, I James, S Vega-Harring, R Dua, M Nguyen, L Steiner, C Adessi, F Michielin, B Bossenmaier, M Weisser, U N Lassen

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

34 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	5406-5415
Number of pages	10
Journal	Clinical Cancer Research
Volume	23
Issue number	18
DOIs	https://doi.org/10.1158/1078-0432.ccr-17-0812
Publication status	Published - 2017

Research programs

EMC MM-03-86-08

Access to Document

10.1158/1078-0432.ccr-17-0812

http://hdl.handle.net/1765/101991

Cite this

Meulendijks, D., Jacob, W., Voest, EE., Mau-Sorensen, M., Martinez-Garcia, M., Taus, A., Fleitas, T., Cervantes, A., Lolkema, M., Langenberg, M. H. G., de Jonge, M., Sleijfer, S., Han, JY., Calles, A., Felip, E., Kim, SW., Schellens, JHM., Wilson, S., Thomas, M., ... Lassen, U. N. (2017). Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity. Clinical Cancer Research, 23(18), 5406-5415. https://doi.org/10.1158/1078-0432.ccr-17-0812

@article{e436b74cff744be498e3d6d0693028eb,

title = "Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity",

author = "D Meulendijks and W Jacob and EE Voest and M Mau-Sorensen and M Martinez-Garcia and A Taus and T Fleitas and A Cervantes and Martijn Lolkema and Langenberg, {M H G} and {de Jonge}, Maja and Stefan Sleijfer and JY Han and A Calles and E Felip and SW Kim and JHM Schellens and S Wilson and M Thomas and M Ceppi and G Meneses-Lorente and I James and S Vega-Harring and R Dua and M Nguyen and L Steiner and C Adessi and F Michielin and B Bossenmaier and M Weisser and Lassen, {U N}",

year = "2017",

doi = "10.1158/1078-0432.ccr-17-0812",

language = "Undefined/Unknown",

volume = "23",

pages = "5406--5415",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "18",

}

Meulendijks, D, Jacob, W, Voest, EE, Mau-Sorensen, M, Martinez-Garcia, M, Taus, A, Fleitas, T, Cervantes, A, Lolkema, M, Langenberg, MHG, de Jonge, M , Sleijfer, S, Han, JY, Calles, A, Felip, E, Kim, SW, Schellens, JHM, Wilson, S, Thomas, M, Ceppi, M, Meneses-Lorente, G, James, I, Vega-Harring, S, Dua, R, Nguyen, M, Steiner, L, Adessi, C, Michielin, F, Bossenmaier, B, Weisser, M & Lassen, UN 2017, 'Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity', Clinical Cancer Research, vol. 23, no. 18, pp. 5406-5415. https://doi.org/10.1158/1078-0432.ccr-17-0812

TY - JOUR

T1 - Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

AU - Meulendijks, D

AU - Jacob, W

AU - Voest, EE

AU - Mau-Sorensen, M

AU - Martinez-Garcia, M

AU - Taus, A

AU - Fleitas, T

AU - Cervantes, A

AU - Lolkema, Martijn

AU - Langenberg, M H G

AU - de Jonge, Maja

AU - Sleijfer, Stefan

AU - Han, JY

AU - Calles, A

AU - Felip, E

AU - Kim, SW

AU - Schellens, JHM

AU - Wilson, S

AU - Thomas, M

AU - Ceppi, M

AU - Meneses-Lorente, G

AU - James, I

AU - Vega-Harring, S

AU - Dua, R

AU - Nguyen, M

AU - Steiner, L

AU - Adessi, C

AU - Michielin, F

AU - Bossenmaier, B

AU - Weisser, M

AU - Lassen, U N

PY - 2017

Y1 - 2017

U2 - 10.1158/1078-0432.ccr-17-0812

DO - 10.1158/1078-0432.ccr-17-0812

M3 - Article

SN - 1078-0432

VL - 23

SP - 5406

EP - 5415

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 18

ER -